Goldman Sachs has updated its monthly US Director's Cut list, adding Vertex Pharmaceuticals (VRTX) and removing Interactive Brokers (IBKR). The list features 20–25 high-conviction, Buy-rated US stocks, selected for differentiated views and attractive risk-adjusted return potential, focusing on bottom-up fundamental analysis.